Moving The Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice

Interact with an expert during this 1-hour, CME/CE/CPE-certified, live meeting examining recent advances and current best practices in managing patients with myeloproliferative neoplasms. This will include discussions of current recommendations and strategies to support physician collaboration and timely patient referral.

Register today!

Agenda

  • Welcome
  • Driver Mutations, Diagnosis/Contemporary Prognostic Assessments, and Risk-Stratification of MPNs
  • Case Discussions: State-of-the-Art Management of PV and ET
  • Case Discussions: State-of-the-Art Management of MF
  • Closing remarks

Events

Date / Time
Event Details
2/4/2020
12:00 PM

Oncology: Myeloproliferative Neoplasms

Gainesville, FL
Malcolm Randall VA Medical Center Details
4/7/2020
12:00 PM

Oncology: Myeloproliferative Neoplasms

Royal Oak, MI
Beaumont Cancer Center Details

Faculty

Faculty
Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty
Gabriela Hobbs

Assistant Professor
Clinical Director
, Leukemia
Division of Leukemia
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Faculty
Andrew Kuykendall, MD

Assistant Professor
Department of Oncologic Sciences
Morsani College of Medicine
Assistant Member, Malignant Hematology
H. Lee Moffitt Cancer Center
Tampa, Florida

Faculty
Stephen Oh, MD

Assistant Professor
Division of Hematology
Department of Medicine
Washington University School of Medicine
St Louis, MO

Goal Statement
The goal of this activity is to improve participants’ knowledge and competence of regarding the management of patients with polycythemia vera, myelofibrosis, or essential thrombocythemia.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with polycythemia vera, myelofibrosis, or essential thrombocythemia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select optimal, individualized treatment for patients with MPNs based on recent advances and evolving best practices to maximize clinical outcomes
  • Integrate emerging agents and regimens for MPNs into routine practice as clinically appropriate
  • Develop an evidence-based treatment plan to improve outcomes in the treatment of MPNs
  • Develop strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion
  • Refer appropriate patients with MPNs to select ongoing clinical trials of novel agents and strategies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Pharmacist Continuing Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Live Meeting Universal Activity Number - JA4008176-0000-19-045-L01-P
Webinar Universal Activity Number - JA4008176-0000-19-046-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.